Drakulic, Danijela; Schwirtlich, Marija; Petrovic, Isidora; Mojsin, Marija; Milivojevic, Milena; Kovacevic-Grujicic, Natasa; Stevanovic, Milena published the artcile< Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma>, Application In Synthesis of 112-63-0, the main research area is BMP signaling; GBM subtypes; Hippo signaling; Notch signaling; RA signaling; SHH signaling; TGFβ signaling; Wnt/β-catenin signaling; glioblastoma.
Glioblastoma (GBM) is the most common and highly lethal type of brain tumor, with poor survival despite advances in understanding its complexity. After current standard therapeutic treatment, including tumor resection, radiotherapy and concomitant chemotherapy with temozolomide, the median overall survival of patients with this type of tumor is less than 15 mo. Thus, there is an urgent need for new insights into GBM mol. characteristics and progress in targeted therapy in order to improve clin. outcomes. The literature data revealed that a number of different signaling pathways are dysregulated in GBM. In this review, we intended to summarize and discuss current literature data and therapeutic modalities focused on targeting dysregulated signaling pathways in GBM. A better understanding of opportunities for targeting signaling pathways that influences malignant behavior of GBM cells might open the way for the development of novel GBM-targeted therapies.
Cells published new progress about 112-63-0. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Application In Synthesis of 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics